IMS Health — Q3 2015 Earnings Presentation
18 slides from IMS Health's earnings presentation, Oct 29, 2015
Slide 1: IMS Health Q3 2015 Earnings Call
IMS Health Q3 2015 Earnings Call October 29, 2015 0
Slide 2: Legal
Legal This presentation should be viewed in conjunction with IMS Health’s Q3 2015 earnings call Safe Harbor Statement This presentation Thi t ti includes i l d “forward-looking “f d l ki statements”, t t t ” including i l di statements t t t regarding di future f t fi financial i l and d operating t
Slide 3: 3rd Quarter Results
3rd Quarter Results $M Revenue Adjusted EBITDA +23.0% +8.6% @ CFx @ CFx $735 $656 $218 $221 Q3 2015 Q3 2014 Q3 2015 Q3 2014 Note: Dollars are at actual foreign exchange rates. CFx is constant currency. EBITDA is “Adjusted EBITDA” as calculated in the appendix of this presentation 2 IMS Health Confid
Slide 4: 3rd Quarter Offering Revenue
3rd Quarter Offering Revenue Offering 3rd Quarter Versus Prior Year Constant $M 2015 2014 Reported Currency Information $373 $382 8.9% (2.3%) Technology Services $362 $274 42.4% 31.9% Total $735 $656 23.0% 12.0% Note: Dollars are at actual foreign exchange rates 3 IMS Health Confidential
Slide 5: 3rd Quarter Geographic Revenue
3rd Quarter Geographic Revenue Geography 3rd Quarter Versus Prior Year Constant $M 2015 2014 Reported Currency Developed Markets $614 $547 21.5% 12.2% Emerging Markets $121 $109 30.5% 11.2% Total $735 $656 23.0% 12.0% Note: Dollars are at actual foreign exchange rates Prior year adjusted to conform
Slide 6: 3rd Quarter EBITDA
3rd Quarter EBITDA 3rd Quarter Versus Prior Year Constant $M 2015 2014 Reported Currency Adjusted EBITDA (1) $218 $221 8.6% (1.5%) Adjusted EBITDA margin 29.6% 33.7% (396) bps (409) bps Note: Dollars are at actual foreign exchange rates (1) See reconciliations of non-GAAP items in appendix 5 IMS Hea
Slide 7: 3rd Quarter P&L
3rd Quarter P&L At reported FX rates $M (except per share data) 2015 2014 Net Income $43 $47 Diluted Earnings per Share $0.13 $0.14 Adjusted Net Income (1) $129 $125 Adjusted Diluted Earnings per Share (1) $0.38 $0.37 (1) See reconciliations of non-GAAP items in appendix 6 IMS Health Confidential
Slide 8: Year-to-date Revenue
Year-to-date Revenue Offering Year-to-date Versus Prior Year Constant $M 2015 2014 Reported Currency Information $1,101 $1,149 7.1% (4.2%) Technology Services $1 008 $1,008 $814 33 9% 33.9% 23 8% 23.8% Total $2,109 $1,963 18.3% 7.4% Geography Year-to-date Versus Prior Year Developed Markets $1,760 $
Slide 9: Year-to-date P&L
Year-to-date P&L $M (except per share data) 2015 2014 Adjusted EBITDA (1) $654 $664 Adjusted EBITDA margin 31.0% 33.8% Net Income / (Loss) $388 $(197) Diluted Earnings / (Loss) per Share $1 14 $1.14 $(0 63) $(0.63) Adjusted Net Income (1) $390 $329 Adjusted Diluted EPS (1) $1.15 $1.02 (1) See reconc
Slide 10: 3rd Quarter Balance Sheet Items & Metrics
3rd Quarter Balance Sheet Items & Metrics $M 2015 2014 Cash & Cash Equivalents q $394 $390 (1) Principal Balance of Debt (2) $4,296 $3,816 (1) Net Debt $3,902 $3,426 (1) Gross Leverage Ratio 5.0x 4.3x (1) Net Cash Provided by Operating Activities $111 $191 Capital Expenditures and Additions to Defer
Slide 11: 2015 Guidance
2015 Guidance Full-Year 2015 Revenue Growth Constant Currency 19 - 20% Reported (1) ~10% Adjusted EBITDA Growth Constant Currency ~11% Reported (1) ~1% Adjusted Net Income Growth Constant Currency 22 - 23% Reported (1) 10 - 11% Adjusted Diluted EPS Constant Currency 17 - 18% Reported (1) 5 - 6% (1)
Slide 12: Q&A
Q&A 11
Slide 13: Appendix: Non-GAAP Financial Measures
Appendix: A di Non-GAAP N GAAP Financial Measures 12
Slide 14: Net Income (Loss) to Adjusted EBITDA
Net Income (Loss) to Adjusted EBITDA Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2015 2014 2015 2014 Net Income (Loss) $ 43 $ 47 $ 388 $ (197) Provision for ((benefit from)) income taxes 8 11 ((219)) ((141)) Other (income) loss, net (6) (7) (16) 281 Interest expens
Slide 15: Net Income (Loss) to Adjusted Net Income & Per Share Data
Net Income (Loss) to Adjusted Net Income & Per Share Data Three Months Ended Nine Months Ended September 30, September 30, (in millions, except per share data) 2015 2014 2015 2014 Net Income (Loss) $ 43 $ 47 $ 388 $ (197) Provision for (benefit from) income taxes 8 11 (219) (141) Amortization associ
Slide 16: Unlevered Free Cash Flow
Unlevered Free Cash Flow Three Months Ended Nine Months Ended September 30, September 30, ((in millions)) 2015 2014 2015 2014 Net Cash Provided by (Used in) Operating Activities $ 111 $ 191 $ 326 $ (37) Capital expenditures (4) (14) (29) (59) Additions to computer software (34) (26) (87) (70) F Free
Slide 17: Gross Leverage Ratio
Gross Leverage Ratio (in millions) Gross Debt as of September 30, 2015 $ 4,296 Adjusted EBITDA for the year ended December 31, 31 2014 878 Less: Adjusted EBITDA for the nine months ended September 30, 2014 (664) Add: Adjusted EBITDA for the nine months ended September 30, 2015 654 Adjusted EBITDA fo
Slide 18: Non-GAAP Adjustments By Income Statement Line Items
Non-GAAP Adjustments By Income Statement Line Items Three Months Th M th Ended E d d Nine M Ni Months th Ended E d d September 30, September 30, (in millions) 2015 2014 2015 2014 Non-GAAP adjustments included in: Operating costs of information, exclusive of depreciation and $ 1 $ 2 $ 3 $ 19 amortiza